Oral Mucositis (OM) continues to be an oncologic challenge in the context of antineoplastic
therapy for head and neck cancer (HNC) treatment. It is a dose-limiting toxicity of …

Background Palifermin, a recombinant keratinocyte growth factor promotes thickening of the
mucosa, minimising severity of mucositis caused by chemotherapy and radiotherapy …

Oral mucositis (OM) is a complication of head and neck cancer (HNC) therapy with negative
impact on the quality of life. Although definitive treatment has not yet been established, there …

Background Transplant related toxicity is a major therapeutic challenge. We have previously
reported that the toxicity of chemotherapy is largely not directly because of the drugs …

Background: Oral Mucositis (OM) is an acute debilitating dose limiting toxicity of
Radiotherapy/Radiochemotherapy (RT/RCT) in management of Head and Neck Cancer …

Background: The primary objective was to determine whether topically administered
Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration …

Objectives This study aimed to assess the cost-effectiveness of photobiomodulation therapy
(PBMT) in association with a Preventive Oral Care Program (POCP) compared with POCP …

High‐dose melphalan followed by autologous stem cell transplantation remains the
standard of care for eligible patients with multiple myeloma, but disease response and …

Objective To examine the comparative efficacy and safety of interventions for preventing
chemotherapy-induced oral mucositis (OM) in adult cancer patients. Methods We searched …

Autologous hematopoietic cell transplantation (AHCT) has presented a revolutionary
advance in the management of hematologic malignancies with low toxicity. However, oral …